MEDISPA.PRO
Ministry of Health code: A18.05.001 Axis M2 · Detoxification and biotransformation CEBM: Level A (Blood purification and detoxification)

Membrane therapeutic plasmapheresis (haemocorrection)

Membrane Therapeutic Plasmapheresis

Industry clinical and economic procedure passport. Full biological mechanism (MoA), patient preparation protocol, first-choice equipment fleet, integration into the resort's master treatment rooms and market price benchmarks.

To the procedure catalogue Equipment fleet Integration treatment rooms Rates and economics
Session duration
90 min
Turnover: ~105 min
Recommended course
10 sessions
2–3 procedures 48–72 hours apart
Throughput capacity
5 pts
per 8-hour shift
Median rate
—
— – —
Course cost
—
at market median
Publication volume
Level A
10 publ. in PubMed

Clinical profile

Removal of blood plasma with return of cells and, in plasma exchange, replacement with albumin or plasma. Indications with a good evidence base are neurological and immune diseases according to the American Society for Apheresis (ASFA) guidelines; use for "rejuvenation" is being studied in small RCTs with conflicting results.

Every statement links to a publication in the list below. This is a snapshot of published research, not a final assessment of the method: international practice and integrated protocols often run ahead of official publications. Draft based on published research; requires review by a physician. Revision: 2026-10-17.

Mechanism of action

  • Plasmapheresis rapidly changes levels of pro-inflammatory and other circulating ageing-related molecules. [10]
  • Removal of antibodies and inflammatory mediators underlies use in autoimmune and neurological diseases. [1]

Where studies show an effect

  • Clinical indications are systematised in the ASFA guidelines: the 10th edition covers 93 diseases and 183 graded indications. [1, 2]
  • Guillain–Barré syndrome: markedly better recovery than with supportive care, with no increase in serious adverse events. [3]
  • Acute myasthenia: response rate higher than with immunoglobulin. [4]
  • Acute-on-chronic liver failure: better survival at 1, 3 and 12 months. [5]
  • Moderate Alzheimer's disease: plasma exchange with albumin slowed cognitive and functional decline (AMBAR RCT). [8]
  • Biological age in healthy people over 50: in a small RCT, plasma exchange, especially with immunoglobulin, improved 15 epigenetic clocks. [9]

Open questions and study limitations

  • Plasmapheresis without replacement in healthy donors did not rejuvenate epigenetic clocks; it accelerated some of them (GrimAge, Hannum, DunedinPACE). [10]
  • Data on "rejuvenation" come from dozens of participants; large studies of long-term safety are needed. [9, 10]
  • In AMBAR there was no effect in patients with mild Alzheimer's disease. [8]
  • In ANCA-associated vasculitis overall, plasma exchange did not reduce mortality; benefit is limited to severe renal involvement. [7, 6]

Safety

  • In an RCT in healthy people over 50, long-term plasma exchange was safe: two adverse events required discontinuation, one was related to immunoglobulin. [9]
  • In Guillain–Barré syndrome serious adverse events did not increase, but the risk of relapse in the first 6–12 months was slightly higher. [3]

Protocol in studies

  • RCT in healthy people over 50: plasma exchange every two weeks (with or without immunoglobulin) or monthly, versus placebo. [9]
  • RCT in donors: 4 or 8 plasmapheresis procedures without replacement over 18 weeks, at least 14 days apart. [10]
Contraindications. Contraindications and the choice of replacement solutions are determined by the transfusiologist; they are not given in study abstracts.

Equipment fleet and fit-out

Certified first-choice medical equipment and compatible device systems

Equipment registry
Base configuration (Hero Device)
Hemofenix / Plasauto Sigma membrane plasmapheresis device

Device platform with proven validation of the biological response. Includes built-in biofeedback sensor systems, patient protection protocols and precision dosing of exposure.

Certification: Russian Ministry of Health registration certificate / CE Medical Device Directive Class IIa/IIb.
Compatible platforms in the MEDISPA.PRO registry
Plasmapheresis AMPld-"TT GEMOFENIKS"
Medical device, Roszdravnadzor registration certificate / CE
In the registry →
Refrigerated centrifuge (provided for medical organisations performing extracorporeal haemocorrection and photohaemotherapy procedures using a refrigerated centrifuge)
Medical device, Roszdravnadzor registration certificate / CE
In the registry →
Lidkor therapeutic chair
Medical device, Roszdravnadzor registration certificate / CE
In the registry →
Device for rapid thawing, warming and warm storage of plasma, blood and infusion solutions
Medical device, Roszdravnadzor registration certificate / CE
In the registry →

Architectural integration and treatment rooms

Resort rooms housing the treatment station (with SanPiN norms and MEP loads)

All treatment rooms →
1.3.4 25.0 m² · Class B

Plasmapheresis room

General therapeutic interventions and high-tech therapy · Equipment: 2 754 741 ₽

Treatment room passport →

Unit economics and resort price benchmarks

Market analysis based on a sample of premium sanatoriums, wellness hotels and preventive medicine clinics

Market price corridor
25th percentile (P25) —
Market median —
75th percentile (P75) —

Median of prices in industry facilities' price lists, 2026

Basis of the price benchmark

Market prices for this procedure are not yet available in industry facilities' price lists, so no benchmark is published.

Evidence base

For clinical indications: ASFA guidelines and Cochrane reviews; for "rejuvenation": two small RCTs with opposite results (grade C for this purpose).

Publication level A · Plenty of data
  1. 1.
    Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach From the Writing Committee of the American Society for Apheresis: The Tenth Special Issue.
    J Clin Apher, 2026 · ASFA clinical guidelines, edition 10 · PMID 42747330
    93 diseases and 183 graded indications for therapeutic apheresis.
  2. 2.
    Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue.
    J Clin Apher, 2019 · ASFA clinical guidelines, edition 8 · PMID 31180581
    84 diseases and 157 graded indications; the basis for selecting indications for apheresis.
  3. 3.
    Plasma exchange for Guillain-Barré syndrome.
    Cochrane Database Syst Rev, 2017 · Cochrane systematic review · PMID 28241090
    Guillain–Barré syndrome: with plasma exchange, better recovery and full recovery of strength at one year; slightly higher risk of relapse.
  4. 4.
    Therapeutic Plasma Exchange in Myasthenia Gravis: A Systematic Literature Review and Meta-Analysis of Comparative Evidence.
    Front Neurol, 2021 · Systematic review and meta-analysis · PMID 34531809
    Acute myasthenia and preparation for thymectomy: response to plasma exchange is higher than to immunoglobulin; mortality does not differ.
  5. 5.
    Therapeutic Plasma Exchange in Patients With Acute-On-Chronic Liver Failure Improves Survival-An Updated Meta-Analysis.
    Liver Int, 2025 · Systematic review and meta-analysis · PMID 40265656
    Acute-on-chronic liver failure: better survival at 1, 3 and up to 12 months.
  6. 6.
    Plasma exchange as an adjunctive therapy in anti-neutrophil cytoplasm antibody-associated vasculitis.
    Expert Rev Clin Immunol, 2023 · Meta-analysis · PMID 36860127
    ANCA-associated vasculitis: plasma exchange is appropriate in severe renal involvement and pulmonary haemorrhage.
  7. 7.
    Efficacy of plasma exchange for antineutrophil cytoplasmic antibody-associated systemic vasculitis: a systematic review and meta-analysis.
    Arthritis Res Ther, 2021 · Systematic review and meta-analysis · PMID 33446268
    ANCA-associated vasculitis: plasma exchange was not associated with mortality, remission or adverse events.
  8. 8.
    A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study.
    Alzheimers Dement, 2020 · RCT, phase II (AMBAR) · PMID 32715623
    Moderate Alzheimer's disease: 61–71 % less decline on cognitive and functional scales; no effect in the mild form.
  9. 9.
    Multi-Omics Analysis Reveals Biomarkers That Contribute to Biological Age Rejuvenation in Response to Single-Blinded Randomized Placebo-Controlled Therapeutic Plasma Exchange.
    Aging Cell, 2025 · RCT, placebo-controlled · PMID 40424097
    42 healthy people over 50: plasma exchange was safe, 15 epigenetic clocks showed rejuvenation, best of all with immunoglobulin.
  10. 10.
    Human clinical trial of plasmapheresis effects on biomarkers of aging (efficacy and safety trial).
    Sci Rep, 2025 · RCT · PMID 40592961
    Plasmapheresis without replacement in donors lowered lipids but did not rejuvenate epigenetic clocks; it accelerated some of them.

Publications were found in PubMed; titles and journals are given verbatim, conclusions are a brief summary of the abstracts under the conditions of the specific studies. The level shows the volume of published data, not the value of the method: A — Plenty of data: consistent systematic reviews and meta-analyses of RCTs; B — Some data: reviews or several RCTs, results are heterogeneous; C — Little data: single RCTs or controlled studies; D — Scarce data: mainly reviews, observational and experimental studies. The passport is updated as new work is published and with regard to international practice.